title: [Active psoriatic arthritis during pregnancy: challenges and limitations of pharmacotherapy].
abstract: Cases of psoriatic arthritis coexisting with pregnancy are sparse and therefore little is known about the fetal effect of medication in women with psoriatic arthritis. As a rule, drugs and dosages are minimized in these patients. Among disease-modifying antirheumatic drugs, cyclosporine and sulphasalazine are preferred. Methotrexate and leflunomide are strictly contraindicated and must be withdrawn 3 months or 2 years, respectively, before a pregnancy is planned. Psoriatic arthritis may be treated during pregnancy with glucocorticosteroids, especially with prednisone or prednisolone. We present the case ofa 40-year-old gravida with psoriatic arthritis which exacerbated during the first trimester of pregnancy. Therapeutic implications in such cases are discussed.
authors.affiliation: Klinika Reumatologii i Chorób Wewnetrznych Akademickiego Szpitala Klinicznego im. Mikulicza-Radeckiego ul. Borowska 213, 50-556 Wrocław.
authors.forename: Agnieszka
authors.initials: A
authors.lastname: Matuszewska
authors.forename: Maria
authors.initials: M
authors.lastname: Misterska-Skóra
authors.forename: Piotr
authors.initials: P
authors.lastname: Wiland
mesh_terms: D000328:Adult; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D015535:Arthritis, Psoriatic / Q000188:drug therapy*; D000075202:Contraindications; D016572:Cyclosporine / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007555:Isoxazoles; D000077339:Leflunomide; D008727:Methotrexate; D011239:Prednisolone / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy*; D012460:Sulfasalazine / Q000627:therapeutic use
chemical_list: D018501:Antirheumatic Agents; D007555:Isoxazoles; D012460:Sulfasalazine; D016572:Cyclosporine; D011239:Prednisolone; D000077339:Leflunomide; D011241:Prednisone; D008727:Methotrexate